Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.
Phase of Trial: Phase III
Latest Information Update: 14 Jul 2016
Price : $35 *
At a glance
- Drugs Measles mumps and rubella virus vaccine (Primary)
- Indications Measles; Mumps; Rubella
- Focus Adverse reactions; Registrational; Therapeutic Use
- 07 Jul 2016 Status changed from recruiting to completed.
- 30 Nov 2013 New trial record